NeOnc Technologies Reports Q2 Results; NEO100 Phase 2a Topline Aug 12

What Happened

• On August 10, 2026 NeOnc Technologies Holdings, Inc. issued a press release (filed on Form 8-K) reporting its second-quarter financial results and confirming that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. The press release is included in the filing as an exhibit.

Key Details

• Form 8-K filed and press release issued on August 10, 2026 (Exhibit 99.1; filing also lists Exhibit 99.2).
• Item 2.02: Company reported second-quarter financial results in the press release.
• Item 2.02: Company confirmed topline data from the fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.
• Item 7.01: Regulation FD disclosure was made in connection with the press release.

Why It Matters

• Quarterly results provide an updated view of the company’s recent financial performance; investors should read the August 10 press release for the revenue, expense and earnings details.
• The August 12 presentation of topline Phase 2a NEO100 data is a near-term clinical milestone that may affect investor perception of NeOnc’s development progress. Watch that presentation for outcomes and any follow-up guidance the company provides.